Mary Kay to invest $20 million in its Indian entry

13 Sep 2007

1

New Delhi: US-based global direct-selling cosmetic major Mary Kay Inc has announced its plans to enter India, with an investment of $20 million over the next five years.

The direct-selling major will operate via its Indian subsidiary, Mary Kay Cosmetics India Pvt Ltd., and will use its investment to set up centres, develop its product portfolio, and train beauty consultants.

Mary Kay''s introduction to the Indian market is marked by the launch of a product line of around 60 products, designed specifically for the Indian market. The company plans to expand the portfolio shortly. It has also set up a beauty centre in Delhi to train consultants.

According to KK Chua, president, Aasia-Pacific, Mary Kay, the company will invest $6-$7 million in its first year of operation.

Latest articles

Sigma Advanced to acquire UK aerospace supplier Bromford for ₹153 crore

Sigma Advanced to acquire UK aerospace supplier Bromford for ₹153 crore

Akasa Air plans ₹1,050 crore fundraising to support growth amid higher costs

Akasa Air plans ₹1,050 crore fundraising to support growth amid higher costs

AI startup Reflection signs over $1 billion computing deal with Nebius

AI startup Reflection signs over $1 billion computing deal with Nebius

Tata Power explores $450 million overseas loan for business operations

Tata Power explores $450 million overseas loan for business operations

TCS wins technology contract for New York JFK Airport’s $19 billion terminal

TCS wins technology contract for New York JFK Airport’s $19 billion terminal

South Korean firms unveil $195 billion investment in AI and advanced industries

South Korean firms unveil $195 billion investment in AI and advanced industries

HCLTech wins $1.14 billion AI transformation deal with European client

HCLTech wins $1.14 billion AI transformation deal with European client

Microsoft launches Frontier to help enterprises accelerate AI adoption

Microsoft launches Frontier to help enterprises accelerate AI adoption

AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs

AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs
View details about the software product Informachine File Manager
View details about the software product Informachine News Trackers